An official website of the United States government
Publication Information
Affiliation
Temple University, Philadelphia, PA.
Authors
Abell TL, Alvarado B, Baxter L, Belt P, Bernard C, Brown A, Clarke JO, Connery S, Culler S, DeVole N, Dhalla S, Dodge J, Donithan M, Earle K, Farrugia G, Garay G, Gomez Y, Grover M, Hallinan E, Hall S, Hamilton F, Hamilton FA, Hasler WL, Hatter L, Herman W, Howard R, Isaacson M, James S, Kim Y, Kirkeby K, Koch KL, Kraftson A, Lee C, Lee LA, Lin M, Mauer A, May PK, McCallum RW, Miriel L, Miriel LA, Nguyen LAB, NIDDK Gastroparesis Clinical Research Consortium (GpCRC), Nowotny L, Orlando C, Orthey P, Palit A, Parkman HP, Pasricha PJ, Ponting K, Romero R, Rothberg AE, Sarosiek I, Serrano J, Snape WJ, Stein E, Stein EM, Sternberg A, Stuart P, Tonascia J, Torrance R, Van Natta M, Van Natta ML, Vega N, Wagoner A, Wilson L, Wootten S, Yates KP, Yee G
Studies
Citation
Pasricha PJ, Yates KP, Sarosiek I, McCallum RW, Abell TL, Koch KL, Nguyen LAB, Snape WJ, Hasler WL, Clarke JO, Dhalla S, Stein EM, Lee LA, Miriel LA, Van Natta ML, Grover M, Farrugia G, Tonascia J, Hamilton FA, Parkman HP, NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. Gastroenterology 2018 Jan;154(1):65-76.e11. Epub 2017 Oct 28.Abstract
There are few effective treatments for nausea and other symptoms in patients with gastroparesis and related syndromes. We performed a randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant to reduce symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome.